Home » Stocks » AXDX

Accelerate Diagnostics, Inc. (AXDX)

Stock Price: $8.23 USD 0.14 (1.73%)
Updated November 24, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 469.35M
Revenue (ttm) 11.53M
Net Income (ttm) -80.63M
Shares Out 57.03M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $8.23
Previous Close $8.09
Change ($) 0.14
Change (%) 1.73%
Day's Open 8.20
Day's Range 8.13 - 8.49
Day's Volume 274,764
52-Week Range 4.53 - 19.11

More Stats

Market Cap 469.35M
Enterprise Value 539.41M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 57.03M
Float 29.43M
EPS (basic) -1.46
EPS (diluted) -1.46
FCF / Share -0.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 15.53M
Short Ratio 90.17
Short % of Float 52.78%
Beta 2.67
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 40.72
PB Ratio n/a
Revenue 11.53M
Operating Income -66.89M
Net Income -80.63M
Free Cash Flow -55.46M
Net Cash -70.06M
Net Cash / Share -1.23
Gross Margin 38.17%
Operating Margin -580.40%
Profit Margin -699.60%
FCF Margin -481.23%
ROA -33.25%
ROE n/a
ROIC -31.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Overweight

Price Target

$15.00*
(82.26% upside)
Low
10.0
Current: $8.23
High
20.0
Target: 15.00
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue9.305.674.180.250.150.120.050.241.122.25
Revenue Growth63.97%35.74%1597.97%67.35%20.49%154.17%-79.66%-78.95%-50.07%-
Gross Profit4.402.483.180.250.150.120.050.241.122.25
Operating Income-72.83-80.37-64.18-66.50-45.55-30.99-15.31-5.35-0.410.61
Net Income-84.31-88.33-64.03-66.37-45.50-30.93-15.28-5.31-0.380.64
Shares Outstanding54.5154.4954.0751.2845.0043.6337.6012.4610.7910.41
Earnings Per Share-1.55-1.62-1.18-1.29-1.01-0.71-0.41-0.43-0.040.06
Operating Cash Flow-64.79-67.76-55.75-53.41-35.13-18.79-9.75-0.820.45-0.79
Capital Expenditures-0.33-1.00-2.97-2.41-3.66-1.93-1.16-0.10-0.08-0.05
Free Cash Flow-65.12-68.75-58.71-55.82-38.78-20.72-10.91-0.910.37-0.84
Cash & Equivalents10816610977.7613266.6841.9914.260.780.28
Total Debt134120--0.010.16----
Net Cash / Debt-25.6246.4010977.7613266.5241.9914.260.780.28
Assets13418512682.8513969.8043.4317.216.266.27
Liabilities1421286.815.046.313.811.912.381.451.36
Book Value-7.3857.3811977.8213365.9941.5214.844.824.91
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Accelerate Diagnostics, Inc.
Country United States
Employees 275
CEO Jack Phillips

Stock Information

Ticker Symbol AXDX
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: AXDX
IPO Date November 18, 1996

Description

Accelerate Diagnostics, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.